{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T14:53:32Z","timestamp":1779288812286,"version":"3.51.4"},"reference-count":73,"publisher":"MDPI AG","issue":"17","license":[{"start":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T00:00:00Z","timestamp":1756166400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diagnostics"],"abstract":"<jats:p>Urothelial carcinoma in situ (UCIS) is a high-grade non-muscle-invasive neoplasm with significant clinical implications due to its potential for progression to muscle-invasive disease. Accurate diagnosis and risk stratification are crucial for appropriate management, particularly given the variability in response to intravesical Bacillus Calmette-Gu\u00e9rin (BCG) therapy. While the diagnosis of UCIS primarily relies on morphological criteria, immunohistochemical (IHC) markers serve as valuable ancillary tools, particularly in challenging cases. Markers such as CK20, CD44, p53, and Ki-67 have been extensively studied, though none demonstrate complete sensitivity or specificity. Additionally, molecular classification has identified luminal and basal subtypes, with potential prognostic and therapeutic implications. Recent studies have also explored predictive biomarkers for BCG response, including PD-L1, whose expression correlates with recurrence and potential responsiveness to immune checkpoint inhibitors. Emerging targeted therapies, such as enfortumab vedotin, have shown promise, with nectin-4 overexpression observed in most UCIS cases. Despite these advancements, challenges remain, including interobserver variability in morphological assessment, heterogeneous IHC methodologies, and the need for standardized molecular testing. This review highlights the current understanding of diagnostic, prognostic, and predictive tissue biomarkers in UCIS, underscoring the potential role of molecular profiling in guiding personalized treatment strategies. Future research should focus on refining biomarker-driven classification systems to improve risk stratification and therapeutic decision-making in UCIS patients.<\/jats:p>","DOI":"10.3390\/diagnostics15172163","type":"journal-article","created":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T14:18:49Z","timestamp":1756217929000},"page":"2163","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Diagnostic, Prognostic, and Predictive Tissue Biomarkers in Urothelial Carcinoma In Situ: A Narrative Review"],"prefix":"10.3390","volume":"15","author":[{"given":"Francesca","family":"Sanguedolce","sequence":"first","affiliation":[{"name":"Pathology Unit, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelo","family":"Cormio","sequence":"additional","affiliation":[{"name":"Department of Urology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Universit\u00e0 Politecnica Delle Marche, Via Conca 71, 60126 Ancona, Italy"},{"name":"Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8733-9933","authenticated-orcid":false,"given":"Magda","family":"Zanelli","sequence":"additional","affiliation":[{"name":"Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9841-7856","authenticated-orcid":false,"given":"Maurizio","family":"Zizzo","sequence":"additional","affiliation":[{"name":"Surgical Oncology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2299-5160","authenticated-orcid":false,"given":"Andrea","family":"Palicelli","sequence":"additional","affiliation":[{"name":"Pathology Unit, Azienda USL-IRCCS di Reggio Emilia, 42123 Reggio Emilia, Italy"},{"name":"Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia, 41121 Modena, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugo Giovanni","family":"Falagario","sequence":"additional","affiliation":[{"name":"Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Milanese","sequence":"additional","affiliation":[{"name":"Department of Urology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Universit\u00e0 Politecnica Delle Marche, Via Conca 71, 60126 Ancona, Italy"},{"name":"Urology Unit, AST 5, Via degli Iris 1, 63100 Ascoli Piceno, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea Benedetto","family":"Galosi","sequence":"additional","affiliation":[{"name":"Department of Urology, Azienda Ospedaliero-Universitaria Ospedali Riuniti Di Ancona, Universit\u00e0 Politecnica Delle Marche, Via Conca 71, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberta","family":"Mazzucchelli","sequence":"additional","affiliation":[{"name":"Section of Pathological Anatomy, Department of Biomedical Sciences and Public Health, United Hospitals, Universit\u00e0 Politecnica delle Marche, 60126 Ancona, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luigi","family":"Cormio","sequence":"additional","affiliation":[{"name":"Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy"},{"name":"Department of Urology, Bonomo Teaching Hospital, 76123 Andria, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Carrieri","sequence":"additional","affiliation":[{"name":"Department of Urology and Renal Transplantation, Policlinico Foggia, University of Foggia, 71122 Foggia, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"952","DOI":"10.5858\/arpa.2022-0509-RA","article-title":"Recent Advances in Genitourinary Tumors: Updates From the 5th Edition of the World Health Organization Blue Book Series","volume":"148","author":"Riddle","year":"2024","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_2","first-page":"499","article-title":"Carcinoma in situ","volume":"19","author":"Lamm","year":"1992","journal-title":"Urol. Clin. N. Am."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"European Association of Urology (EAU) (2024, January 5\u20138). EAU Guidelines. Proceedings of the EAU Annual Congress Paris 2024 Ed., Paris, France.","DOI":"10.1016\/B978-0-323-99934-2.00022-X"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Fujii, S., Ishida, M., Komura, K., Nishimura, K., Tsujino, T., Saito, T., Taniguchi, Y., Murakawa, T., Azuma, H., and Hirose, Y. (2023). Expression of Preferentially Expressed Antigen in Melanoma, a Cancer\/Testis Antigen, in Carcinoma In Situ of the Urinary Tract. Diagnostics, 13.","DOI":"10.3390\/diagnostics13243636"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.pathol.2020.10.001","article-title":"Urothelial carcinoma in situ: Diagnostic update","volume":"53","author":"McKenney","year":"2021","journal-title":"Pathology"},{"key":"ref_6","unstructured":"Board WCoTE (2022). Urothelial carcinoma in situ. Urinary and Male Genital Tumours, International Agency for Research on Cancer. [5th ed.]. Available online:https:\/\/publications.iarc.who.int\/Book-And-Report-Series\/Who-Classification-Of-Tumours\/Urinary-And-Male-Genital-Tumours-2022."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00428-013-1378-4","article-title":"Different subtypes of carcinoma in situ of the bladder do not have a different prognosis","volume":"462","author":"Jacquet","year":"2013","journal-title":"Virchows Arch."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.mpdhp.2024.02.001","article-title":"How to distinguish between reactive and neoplastic flat urothelial lesions","volume":"30","author":"Oszwald","year":"2024","journal-title":"Diagn. Histopathol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1097\/00000478-200107000-00007","article-title":"In situ adenocarcinoma of the bladder","volume":"25","author":"Chan","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Zhou, H., Guo, C.C., and Ro, J.Y. (2021). Flat Urothelial Lesions. Urinary Bladder Pathology, Springer.","DOI":"10.1007\/978-3-030-71509-0"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1179\/2047480615Z.000000000329","article-title":"Writing narrative style literature reviews","volume":"24","author":"Ferrari","year":"2015","journal-title":"Med. Writ."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1471-1842.2009.00848.x","article-title":"A typology of reviews: An analysis of 14 review types and associated methodologies","volume":"26","author":"Grant","year":"2009","journal-title":"Health Inf. Libr. J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.5858\/arpa.2022-0493-RA","article-title":"The Application and Pitfalls of Immunohistochemical Markers in Challenging Diagnosis of Genitourinary Pathology","volume":"148","author":"Li","year":"2024","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.anndiagpath.2019.06.002","article-title":"Immunohistochemistry in the workup of bladder biopsies: Frequency, variation and utility of use at an academic center","volume":"41","author":"McIntire","year":"2019","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.humpath.2020.02.008","article-title":"Immunohistochemical staining patterns of Ki-67 and p53 in florid reactive urothelial atypia and urothelial carcinoma in situ demonstrate significant overlap","volume":"98","author":"Nguyen","year":"2020","journal-title":"Hum. Pathol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"152370","DOI":"10.1016\/j.anndiagpath.2024.152370","article-title":"Next-generation sequencing has diagnostic utility in challenging small\/flat urothelial lesions","volume":"73","author":"Pinard","year":"2024","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1097\/PAS.0000000000000240","article-title":"Best practices recommendations in the application of immunohistochemistry in the bladder lesions: Report from the International Society of Urologic Pathology consensus conference","volume":"38","author":"Amin","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1080\/1354750X.2018.1428360","article-title":"Evolving concepts and use of immunohistochemical biomarkers in flat non-neoplastic urothelial lesions: WHO 2016 classification update with diagnostic algorithm","volume":"23","author":"Sanguedolce","year":"2018","journal-title":"Biomarkers"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/s41379-022-01062-2","article-title":"p53 null phenotype is a \u201cpositive result\u201d in urothelial carcinoma in situ","volume":"35","author":"Sangoi","year":"2022","journal-title":"Mod. Pathol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.humpath.2024.04.001","article-title":"Enhancing upper tract urothelial carcinoma diagnosis: Utility of cytokeratin 17 and CK20\/CD44\/p53 immunohistochemical panel","volume":"146","author":"Irwin","year":"2024","journal-title":"Hum. Pathol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.humpath.2012.08.011","article-title":"Immunohistochemistry as an adjunct in the differential diagnosis of radiation-induced atypia versus urothelial carcinoma in situ of the bladder: A study of 45 cases","volume":"44","author":"Oliva","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_22","first-page":"1425","article-title":"Staining patterns of keratins in the human urinary tract","volume":"24","author":"Alonso","year":"2009","journal-title":"Histol. Histopathol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"152413","DOI":"10.1016\/j.prp.2019.04.005","article-title":"Diagnostic and prognostic roles of CK20 in the pathology of urothelial lesions. A systematic review","volume":"215","author":"Sanguedolce","year":"2019","journal-title":"Pathol. Res. Pract."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1097\/00000478-200108000-00013","article-title":"Discriminatory immunohistochemical staining of urothelial carcinoma in situ and non-neoplastic urothelium: An analysis of cytokeratin 20, p53, and CD44 antigens","volume":"25","author":"McKenney","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/01.MP.0000056628.38714.5D","article-title":"Immunohistochemical expression of CK20, p53, and Ki-67 as objective markers of urothelial dysplasia","volume":"16","author":"Castillo","year":"2003","journal-title":"Mod. Pathol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/j.1440-1827.2005.01821.x","article-title":"Utility of cytokeratin 20 and Ki-67 as markers of urothelial dysplasia","volume":"55","author":"Kunju","year":"2005","journal-title":"Pathol. Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1186\/s13000-020-00984-2","article-title":"CK20 versus AMACR and p53 immunostains in evaluation of Urothelial Carcinoma in Situ and Reactive Atypia","volume":"15","author":"Neal","year":"2020","journal-title":"Diagn. Pathol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"290","DOI":"10.5858\/arpa.2019-0550-RA","article-title":"Application and Pitfalls of Immunohistochemistry in Diagnosis of Challenging Genitourinary Cases","volume":"144","author":"Ross","year":"2020","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"153937","DOI":"10.1016\/j.prp.2022.153937","article-title":"Could double stain for p53\/CK20 be a useful diagnostic tool for the appropriate classification of flat urothelial lesions?","volume":"234","author":"Ambrosi","year":"2022","journal-title":"Pathol. Res. Pract."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1186\/1746-1596-4-35","article-title":"Utility of a dual immunostain cocktail comprising of p53 and CK20 to aid in the diagnosis of non-neoplastic and neoplastic bladder biopsies","volume":"4","author":"Yildiz","year":"2009","journal-title":"Diagn. Pathol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.humpath.2023.03.007","article-title":"Urothelial carcinoma in situ with \u201coverriding\u201d features can evade detection by mimicking umbrella cells","volume":"136","author":"Bahceci","year":"2023","journal-title":"Hum. Pathol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/cyt.12332","article-title":"Immunocytochemical staining for p53 and Ki-67 helps to characterise urothelial cells in urine cytology","volume":"27","author":"Aziza","year":"2016","journal-title":"Cytopathology"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/PAI.0000000000000872","article-title":"Urothelial Carcinoma In Situ of the Bladder: Correlation of CK20 Expression With Adaptive Immune Resistance, Response to BCG Therapy, and Clinical Outcome","volume":"29","author":"Lombardo","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.4103\/1742-6413.123784","article-title":"Evaluation of a triple combination of cytokeratin 20, p53 and CD44 for improving detection of urothelial carcinoma in urine cytology specimens","volume":"10","author":"Arville","year":"2013","journal-title":"CytoJournal"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Yoo, D., Min, K.W., Pyo, J.S., and Kim, N.Y. (2023). Diagnostic Roles of Immunohistochemical Markers CK20, CD44, AMACR, and p53 in Urothelial Carcinoma In Situ. Medicina, 59.","DOI":"10.20944\/preprints202308.0323.v1"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1097\/PAS.0000000000001318","article-title":"Carcinoma In Situ With Plasmacytoid Features: A Clinicopathologic Study of 23 Cases","volume":"43","author":"Sangoi","year":"2019","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1097\/PAI.0000000000000334","article-title":"Flat Intraurothelial Neoplasia Exhibiting Diffuse Immunoreactivity for CD44 and Cytokeratin 5 (Urothelial Stem Cell\/Basal Cell Markers): A Variant of Intraurothelial Neoplasia Commonly Associated With Muscle-invasive Urothelial Carcinoma","volume":"25","author":"Mai","year":"2017","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1097\/PAS.0000000000000114","article-title":"Utility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3-CK20\/CD44s\/p53) and \u03b1-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia","volume":"37","author":"Aron","year":"2013","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.humpath.2020.01.004","article-title":"The applicability and utility of immunohistochemical biomarkers in bladder pathology","volume":"98","author":"Akgul","year":"2020","journal-title":"Hum. Pathol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13000-019-0871-8","article-title":"Does the addition of AMACR to CK20 help to diagnose challenging cases of urothelial carcinoma in situ?","volume":"14","author":"Alston","year":"2019","journal-title":"Diagn. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1097\/PAS.0000000000000191","article-title":"Observations on Aron et al\u2019s \u201cUtility of a triple antibody cocktail intraurothelial neoplasm-3 (IUN-3 CK20\/CD44s\/p53) and \u03b1-methylacyl-CoA racemase (AMACR) in the distinction of urothelial carcinoma in situ (CIS) and reactive urothelial atypia","volume":"38","author":"Fellegara","year":"2014","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.anndiagpath.2013.10.006","article-title":"The role of immunohistochemistry in the diagnosis of flat urothelial lesions: A study using CK20, CK5\/6, P53, Cd138, and Her2\/Neu","volume":"18","author":"Jung","year":"2014","journal-title":"Ann. Diagn. Pathol."},{"key":"ref_43","doi-asserted-by":"crossref","unstructured":"Sanguedolce, F., Zanelli, M., Palicelli, A., Bisagni, A., Zizzo, M., Ascani, S., Pedicillo, M.C., Cormio, A., Falagario, U.G., and Carrieri, G. (2023). HER2 Expression in Bladder Cancer: A Focused View on Its Diagnostic, Prognostic, and Predictive Role. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043720"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s00428-018-2354-9","article-title":"Progression of urothelial carcinoma in situ of the urinary bladder: A switch from luminal to basal phenotype and related therapeutic implications","volume":"472","author":"Barth","year":"2018","journal-title":"Virchows Arch."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1309\/AJCPKUZ69LXZGFEA","article-title":"Different HER2 protein expression profiles aid in the histologic differential diagnosis between urothelial carcinoma in situ (CIS) and non-CIS conditions (dysplasia and reactive atypia) of the urinary bladder mucosa","volume":"136","author":"Gunia","year":"2011","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/bjc.2012.215","article-title":"Expression of MAGE-A3, NY-ESO-1, LAGE-1 and PRAME in urothelial carcinoma","volume":"107","author":"Zieger","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00428-019-02661-2","article-title":"Evaluation of cancer testis antigen (CT10, PRAME) and MHC I expression in high-grade urothelial carcinoma of the bladder","volume":"476","author":"Hodgson","year":"2020","journal-title":"Virchows Arch."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1097\/PAS.0000000000001944","article-title":"PRAME Expression in Cancer. A Systematic Immunohistochemical Study of >5800 Epithelial and Nonepithelial Tumors","volume":"46","author":"Kaczorowski","year":"2022","journal-title":"Am. J. Surg. Pathol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00428-021-03239-7","article-title":"Clinicopathological significance of claspin overexpression and its efficacy as a novel biomarker for the diagnosis of urothelial carcinoma","volume":"480","author":"Kobayashi","year":"2022","journal-title":"Virchows Arch."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"64","DOI":"10.5858\/arpa.2016-0411-OA","article-title":"CK20 and p53 Immunohistochemical Staining Patterns in Urinary Bladder Specimens With Equivocal Atypia","volume":"142","author":"Shah","year":"2018","journal-title":"Arch. Pathol. Lab. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1097\/PAI.0000000000000401","article-title":"Flat Urothelial Lesions With Atypia: Interobserver Concordance and Added Value of Immunohistochemical Profiling","volume":"26","author":"Lawless","year":"2018","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ccell.2016.05.004","article-title":"Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma","volume":"30","author":"Hedegaard","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","article-title":"Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer","volume":"171","author":"Robertson","year":"2017","journal-title":"Cell"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00428-021-03054-0","article-title":"Intratumoral heterogeneity of surrogate molecular subtypes in urothelial carcinoma in situ of the urinary bladder: Implications for prognostic stratification of high-risk non-muscle-invasive bladder cancer","volume":"479","author":"Garczyk","year":"2021","journal-title":"Virchows Arch."},{"key":"ref_55","doi-asserted-by":"crossref","unstructured":"Sanguedolce, F., Zanelli, M., Palicelli, A., Ascani, S., Zizzo, M., Cocco, G., Bj\u00f6rnebo, L., Lantz, A., Falagario, U.G., and Cormio, L. (2022). Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 1: General Issues and Marker Expression. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147819"},{"key":"ref_56","doi-asserted-by":"crossref","unstructured":"Sanguedolce, F., Zanelli, M., Palicelli, A., Ascani, S., Zizzo, M., Cocco, G., Bj\u00f6rnebo, L., Lantz, A., Landriscina, M., and Conteduca, V. (2022). Are We Ready to Implement Molecular Subtyping of Bladder Cancer in Clinical Practice? Part 2: Subtypes and Divergent Differentiation. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147844"},{"key":"ref_57","first-page":"400","article-title":"Differential diagnosis of urothelial carcinoma in situ from non-neoplastic urothelia: Analysis of CK20, CD44, P53 and Ki67","volume":"30","author":"Asgari","year":"2016","journal-title":"Med. J. Islam. Repub. Iran."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1158\/0008-5472.CAN-20-2336","article-title":"Bladder Tumor Subtype Commitment Occurs in Carcinoma In Situ Driven by Key Signaling Pathways Including ECM Remodeling","volume":"81","author":"Wullweber","year":"2021","journal-title":"Cancer Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1097\/00129039-200609000-00002","article-title":"Cytokeratin 20 and Ki-67 to distinguish carcinoma in situ from flat non-neoplastic urothelium","volume":"14","author":"Yin","year":"2006","journal-title":"Appl. Immunohistochem. Mol. Morphol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","article-title":"EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016","volume":"71","author":"Babjuk","year":"2017","journal-title":"Eur. Urol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.juro.2009.07.016","article-title":"Predicting nonmuscle invasive bladder cancer recurrence and progression in patients treated with bacillus Calmette-Guerin: The CUETO scoring model","volume":"182","author":"Madero","year":"2009","journal-title":"J. Urol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.urology.2008.12.047","article-title":"Recurrence at three months and high-grade recurrence as prognostic factor of progression in multivariate analysis of T1G2 bladder tumors","volume":"73","author":"Palou","year":"2009","journal-title":"Urology"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0022-5347(05)67281-3","article-title":"The 3-month clinical response to intravesical therapy as a predictive factor for progression in patients with high risk superficial bladder cancer","volume":"164","author":"Solsona","year":"2000","journal-title":"J. Urol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.0.CO;2-U","article-title":"Survival of patients with carcinoma in situ of the urinary bladder","volume":"85","author":"Cheng","year":"1999","journal-title":"Cancer"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"34066","DOI":"10.18632\/oncotarget.26122","article-title":"Enhanced expression of PD-L1 in non-muscle-invasive bladder cancer after treatment with Bacillus Calmette-Guerin","volume":"9","author":"Hashizume","year":"2018","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1200\/JCO.2022.40.6_suppl.545","article-title":"PD-L1 expression and BCG response in nonmuscle invasive bladder cancer","volume":"40","author":"Woldu","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.humpath.2022.06.006","article-title":"Precursors of urinary bladder cancer: Molecular alterations and biomarkers","volume":"133","author":"Taylor","year":"2023","journal-title":"Hum. Pathol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/S0022-5347(17)32745-3","article-title":"Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder","volume":"152","author":"Sarkis","year":"1994","journal-title":"J. Urol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/BF00184241","article-title":"P53 accumulation in precursor lesions and early stages of bladder cancer","volume":"12","author":"Grimm","year":"1994","journal-title":"World J. Urol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S0090-4295(03)00236-X","article-title":"Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder","volume":"61","author":"Shariat","year":"2003","journal-title":"Urology"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/PAP.0000000000000239","article-title":"Urothelial Carcinoma In Situ (CIS): New Insights","volume":"26","author":"Akhtar","year":"2019","journal-title":"Adv. Anat. Pathol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1440-1827.2011.02694.x","article-title":"Association between the expression pattern of p16, pRb and p53 and the response to intravesical bacillus Calmette-Guerin therapy in patients with urothelial carcinoma in situ of the urinary bladder","volume":"61","author":"Sato","year":"2011","journal-title":"Pathol. Int."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1097\/PAI.0000000000000938","article-title":"Expression of Nectin-4 in Bladder Urothelial Carcinoma, in Morphologic Variants, and Nonurothelial Histotypes","volume":"29","author":"Lombardo","year":"2021","journal-title":"Appl. Immunohistochem. Mol. Morphol."}],"container-title":["Diagnostics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/17\/2163\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:33:19Z","timestamp":1760034799000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-4418\/15\/17\/2163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,26]]},"references-count":73,"journal-issue":{"issue":"17","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["diagnostics15172163"],"URL":"https:\/\/doi.org\/10.3390\/diagnostics15172163","relation":{},"ISSN":["2075-4418"],"issn-type":[{"value":"2075-4418","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,26]]}}}